Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …

Background Cytokine storm is a marker of coronavirus disease 2019 (COVID-19) illness
severity and increased mortality. Immunomodulatory treatments have been repurposed to …

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

Objective To examine outcomes among patients who were treated with the targeted anti-
cytokine agents, anakinra or tocilizumab, for COVID-19-related cytokine storm (COVID19 …

Objectives To prospectively investigate in patients with severe COVID-19-associated
cytokine storm syndrome (CSS) whether an intensive course of glucocorticoids with or …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Introduction Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to
severe immune response. Treatment targeting this immune response might be beneficial but …

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2),
emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease …

We have read with interest the excellent review by McGonagle et al. discussing the possible
role of hyperinflammation secondary to macrophage activation syndrome (MAS) or cytokine …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …